Evidence map›Paper›PMID 37951209›Full record

ArticleMed (New York, N.Y.)2023

Transforming ovarian cancer care by targeting minimal residual disease.

Amir A Jazaeri, Rachel Grisham, Anne Knisely, Stefani Spranger, Dmitriy Zamarin, R Tyler Hillman, Barrett C Lawson, Kathleen H Burns, Sanghoon Lee, Shannon N Westin and 16 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Med (New York, N.Y.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 5 institutions in 1 country.

Amir A JazaeriUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: aajazaeri@mdanderson.org.
Rachel GrishamMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Anne KniselyUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA.
Stefani SprangerDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Dmitriy ZamarinMemorial Sloan Kettering Cancer Center, New York, NY, USA.
R Tyler HillmanUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA.
Barrett C LawsonUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kathleen H BurnsDana-Farber Cancer Institute, Boston, MA, USA.
Sanghoon LeeUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shannon N WestinUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA.
Enrico MoisoDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Marc J WilliamsMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Neelkanth M BardhanDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA; Break Through Cancer, Cambridge, MA, USA.
Thomas PisanicBreak Through Cancer, Cambridge, MA, USA.
Ursula MatulonisDana-Farber Cancer Institute, Boston, MA, USA.
Britta WeigeltMemorial Sloan Kettering Cancer Center, New York, NY, USA.
IeMing ShihThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
Panagiotis A KonstantinopoulosDana-Farber Cancer Institute, Boston, MA, USA.
Stephanie GaillardThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
Linghua WangUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA.
Carol AghajanianMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Alan D D'AndreaDana-Farber Cancer Institute, Boston, MA, USA.
Paula HammondDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Sohrab ShahMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Kai W WucherpfennigDana-Farber Cancer Institute, Boston, MA, USA.
Karen H LuUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA.
The University of Texas MD Anderson Cancer Center · USMemorial Sloan Kettering Cancer Center · USDana-Farber Cancer Institute · USMassachusetts Institute of Technology · USSidney Kimmel Comprehensive Cancer Center · US

Funding

Training of Academic Gynecologic OncologistsT32CA101642 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ANIL K SOOD, Kathleen Schmeler · 2005 to 2026
$9.2M
NCI NIH HHS T32 CA101642
6 · The paper itself

Abstract

Frontline treatment and resultant cure rates in patients with advanced ovarian cancer have changed little over the past several decades. Here, we outline a multidisciplinary approach aimed at gaining novel therapeutic insights by focusing on the poorly understood minimal residual disease phase of ovarian cancer that leads to eventual incurable recurrences.

Indexed as

Ovarian NeoplasmsCarcinoma, Ovarian EpithelialFemaleHumansNeoplasm, Residual

Identifiers

PMID37951209
PMCPMC11275633
OpenAlexW4388576023

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.